Immune Design (IMDZ) Misses Q4 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Jefferies Cuts Price Target on Immune Design (IMDZ) Following 4Q
March 11, 2016 9:29 AM ESTJefferies maintained a Buy rating on Immune Design (NASDAQ: IMDZ), and cut the price target to $21.00 (from $23.00), following the company's 4Q earnings report. 4Q operating expenses were $13.3M consisting of $8.9M of R&D. This contributed to a net loss of $12.1M compared to... More



